Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-10-09
2007-10-09
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252170, C544S284000, C544S295000, C544S363000
Reexamination Certificate
active
10565066
ABSTRACT:
Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided:wherein R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5and q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.
REFERENCES:
patent: 3937708 (1976-02-01), Mentrup et al.
patent: 3975525 (1976-08-01), Mentrup et al.
patent: 3992537 (1976-11-01), Mentrup et al.
patent: 4891375 (1990-01-01), Lowe, III
patent: 4933447 (1990-06-01), Koono et al.
patent: 5430033 (1995-07-01), Cliffe et al.
patent: 5627177 (1997-05-01), Cliffe et al.
patent: 5965560 (1999-10-01), Glase et al.
patent: 6121267 (2000-09-01), Glase et al.
patent: 6214829 (2001-04-01), Feenstra et al.
patent: 6825189 (2004-11-01), Peters et al.
patent: 6897219 (2005-05-01), Peters et al.
patent: 2002/0094986 (2002-07-01), Chappell et al.
patent: 2004/0048869 (2004-03-01), Chappell et al.
patent: 2004/0072823 (2004-04-01), Peters et al.
patent: 2005/0124625 (2005-06-01), Salvati et al.
patent: 2005/0282236 (2005-12-01), Gaeta et al.
patent: 2005/0287617 (2005-12-01), Gaeta et al.
patent: 308897 (1989-03-01), None
patent: 673927 (1995-09-01), None
patent: 742207 (1996-11-01), None
patent: 0900792 (1999-03-01), None
patent: 1213031 (2002-06-01), None
patent: 2277517 (1994-11-01), None
patent: 2312843 (1997-11-01), None
patent: 58083677 (1983-05-01), None
patent: 63054363 (1988-10-01), None
patent: 2777159 (1998-07-01), None
patent: WO9415919 (1994-07-01), None
patent: WO9415928 (1994-07-01), None
patent: WO97/36893 (1997-10-01), None
patent: WO9741108 (1997-11-01), None
patent: WO9825617 (1998-06-01), None
patent: WO9921834 (1999-05-01), None
patent: WO99/31086 (1999-06-01), None
patent: WO0078716 (2000-12-01), None
patent: WO01/32626 (2001-05-01), None
patent: WO02094203 (2002-11-01), None
patent: WO2004035556 (2004-04-01), None
patent: WO2004041793 (2004-05-01), None
patent: WO2004046124 (2004-06-01), None
patent: WO2004074218 (2004-09-01), None
patent: WO2005014552 (2005-02-01), None
patent: WO2005 040136 (2005-05-01), None
patent: WO2005/087742 (2005-09-01), None
Robichaud et al. Annual Reports in Medicinal Chemistry, vol. 35, pp. 11-20 (2000).
Jones et al. Pharmacology, Biochemistry and Behavior, vol. 71, pp. 555-568 (2002).
Falchi Alessandro
Leslie Colin Philip
Tibasco Jessica
Bernhardt Emily
Glaxo Group Limited
Kinzig Charles M.
McCarthy Mary E.
Sieburth Kathryn L.
LandOfFree
Quinoline and quinazoline derivatives having affinity for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinoline and quinazoline derivatives having affinity for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoline and quinazoline derivatives having affinity for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3837641